The advent of more effective treatment combinations for metastatic hormone-sensitive prostate cancer (mHSPC) has been built on successes in therapy development for metastatic, castration-resistant prostate cancer (mCRPC). Both disease phases hold similar challenges and questions. Is there an optimal therapy sequence to maximize disease control and balance treatment burden? Are there clinical and biologically based subgroups that inform personalized and/or adaptive strategies? How can clinicians interpret data from clinical trials in the context of rapidly evolving technologies? Herein, we review the contemporary landscape of treatment for mHSPC, including disease subgroups informing both intensification and potential deintensification strategies. Furthermore, we provide current insights into the complex biology of mHSPC and discuss the potential clinical application of biomarkers to guide therapy selection and the development of novel personalized approaches.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2023 May [Epub]
Anis A Hamid, Nicolas Sayegh, Bertrand Tombal, Maha Hussain, Christopher J Sweeney, Julie N Graff, Neeraj Agarwal
University of Melbourne, Melbourne, Australia., Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Division of Urology, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium., Division of Hematology & Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL., South Australian Immunogenomics Cancer Institute, Adelaide, Australia., Knight Cancer Institute, Oregon Health and Science University, Portland, OR.